Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in Fgfr2-Driven Cholangiocarcinoma and Other Solid Tumors
Relay therapeutics和Elevar therapeutics宣佈就Lirafugratinib在FGFR2驅動的膽管癌及其他實體瘤中的獨家全球許可協議。
